Get Live Data

Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Sinclair Pharma Share Price
  4. Sinclair Pharma Share Regulatory News
  5. Disclosure under Rule 2.10(c)

Pin to quick picksSinclair Pharma Regulatory News (SPH)

Sinclair Pharma Information
  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disclosure under Rule 2.10(c)

18 Oct 2018 07:00

RNS Number : 4056E
Sinclair Pharma PLC
18 October 2018
 

Toscafund Asset Management LLP

Disclosure under Rule 2.10(c) of The City Code on Takeovers and Mergers

 

Toscafund Asset Management LLP ("Toscafund") provided a non-binding letter of intent to Huadong Medicine Aesthetics Investment (Hong Kong) Limited on 28 August 2018 regarding the proposed acquisition of Sinclair Pharma plc ("Sinclair") as referred to in the announcement of the recommended cash offer on 18 September 2018.

 

The non-binding letter of intent was for 148,613,603 ordinary shares of 1p each in Sinclair Pharma plc.

 

On 16 October 2018 Sinclair announced that following a disposal, Toscafund no longer intended to comply with the letter of intent in respect of 92,000,000 ordinary shares of 1p each in Sinclair Pharma plc.

 

In accordance with Rule 2.10(c) of The City Code on Takeovers and Mergers it is today confirmed that following a further disposal of 56,613,603 ordinary shares of 1p each in Sinclair Pharma plc Toscafund no longer intends to comply with the letter of intent in respect of any ordinary shares of 1p each in Sinclair Pharma plc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGGGMWUUPRGRM
12345678910
Date   Source Headline
28th Mar 20177:15 amRNSHardman Research: Much more streamlined
27th Mar 201710:30 amRNSAppointment of Joint Broker
22nd Mar 20175:29 pmRNSHolding(s) in Company
21st Mar 20177:00 amRNSPreliminary Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
17th Jan 20179:27 amRNSHardman Research: Demanding targets exceeded
17th Jan 20177:00 amRNSPre-Close Trading Update
5th Jan 20177:15 amRNSNotification of full year trading update
17th Nov 201610:39 amRNSDirector/PDMR Shareholding
17th Nov 201610:36 amRNSAdditional Listing
8th Nov 20169:08 amRNSHardman Research: Poised for a long term uplift
8th Nov 20167:05 amRNSHardman Research: Poised for a long term uplift
18th Oct 20165:55 pmRNSHolding(s) in Company
13th Oct 20164:46 pmRNSHolding(s) in Company
5th Oct 20167:00 amRNSDirector/PDMR Shareholding
3rd Oct 20163:56 pmRNSHolding(s) in Company
30th Sep 20162:29 pmRNSTotal Voting Rights
29th Sep 20162:24 pmRNSHolding(s) in Company
28th Sep 20162:23 pmRNSAdditional Listing
27th Sep 20164:14 pmRNSDirector/PDMR Shareholding
27th Sep 20164:12 pmRNSDirector/PDMR Shareholding
26th Sep 20165:04 pmRNSAdditional Listing
22nd Sep 20162:02 pmRNSHolding(s) in Company
21st Sep 20167:00 amRNSHalf-year Report
1st Sep 20167:00 amRNSRestructuring Programme and Board Change
22nd Aug 20167:00 amRNSNotice of Results
19th Jul 20167:00 amRNSTrading Statement
2nd Jun 20167:00 amRNSPresenting at Jefferies Healthcare Conference
31st May 20167:00 amRNSDirector Dealing
24th May 20169:52 amRNSPurchase of shares by Chief Financial Officer
23rd May 20167:00 amRNSDirector Dealing
20th May 201611:43 amRNSOption Awards
20th May 201610:16 amRNSDirector Dealings
20th May 20167:00 amRNSUS Collaboration and Positive Trading Update
19th May 20164:35 pmRNSUS Collaboration and Positive Trading Update
19th May 20162:15 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
19th May 201612:50 pmRNSForm 8.3 - Sinclair Pharma PLC
19th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th May 201611:24 amRNSForm 8.3 - Sinclair Pharma plc
17th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
16th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
13th May 20161:35 pmRNSForm 8.3 - Sinclair Pharma plc
12th May 201612:40 pmRNSForm 8.3 - Sinclair Pharma plc
11th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
10th May 20162:13 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
10th May 20161:56 pmRNSForm 8.3 - Sinclair Pharma plc
9th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th May 201611:25 amPRNForm 8.3 - Sinclair Pharma Plc
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.